CSL FPO [CSL] (CSL.AX)
Makes blood plasma medicines, vaccines, and treatments for serious diseases worldwide.
128.41+0.07%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-51.4%
The outlook
CSL trades at 128.41 with analysts leaning "Buy" on average, though sentiment is moderately mixed rather than strongly bullish. The stock sits near the lower end of its 52-week range and trades below its moving average trend, while the average analyst target sits roughly 9% above the current price. The trailing P/E of 14.6 is relatively modest for the sector.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 16 analysts
Price trendMixed vs its moving averages
52-week range21% of the way from its 52-week low to high
Price targetAvg target +9% vs current price
Analyst price target
~12-month · 16 analysts139.36average target+8.5% vs now
Now 128.41
Low 104.06High 199.35
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
—
52-wk high
275.79
52-wk low
90.00
50-day avg
110.70
200-day avg
147.87
Trailing P/E
14.6